Acorda Therapeutics (NSDQ:ACOR) said this week that the FDA approved its Inbrija device for the intermittent treatment of “off” episodes in people with Parkinson’s disease.
The self-administered, inhaled therapy is designed for people experiencing a re-emergence of Parkinson’s symptoms. These “off” episodes are caused by low levels of dopamine between doses of the standard oral Parkinson’s therapy, carbidopa/levodopa, according to Acorda.
Get the full story at our sister site, Drug Delivery Business News.
The post Acorda wins FDA nod for inhaled Parkinson’s therapy appeared first on MassDevice.
from MassDevice http://bit.ly/2rUqJlR
Cap comentari:
Publica un comentari a l'entrada